Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.
Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.
Amgen (NASDAQ:AMGN) will release its fourth quarter and full year 2022 financial results on January 31, 2023, post-market close. A conference call with management, including CEO Robert A. Bradway, will follow at 4:30 p.m. ET. The call and additional financial presentations will be accessible via the Amgen website.
Amgen, a leader in biotechnology, focuses on developing innovative therapeutics for patients with serious illnesses. The company is recognized as one of the top independent biotech firms and is part of the Dow Jones Industrial Average and Nasdaq-100.
Amgen (NASDAQ:AMGN) has awarded the third Amgen Golden Ticket to Nammi Therapeutics, providing the company with one year of lab space at BioLabs LA at The Lundquist Institute. This initiative aims to accelerate life science startups in Southern California and reflects Amgen's commitment to supporting innovative biotechnology. The award was decided after a competitive pitch event judged by Amgen's scientific leaders, further enhancing the collaborative ecosystem within the Los Angeles biotech community.
Amgen will present at the 2023 J.P. Morgan Healthcare Conference on January 9, 2023, at 6:45 p.m. ET. CEO Robert A. Bradway will lead the presentation, which will be available via a live webcast to media, investors, and the public. The event will also be archived for replay for 90 days. Amgen, a biotechnology pioneer since 1980, focuses on innovative therapeutics for serious illnesses, contributing significantly to health outcomes. The company is part of the Dow Jones Industrial Average and Nasdaq-100, recognized for sustainability and employee satisfaction.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a $25 million milestone payment from Amgen (NASDAQ: AMGN) triggered by the enrollment of the first subject in Amgen's Phase 3 trial of olpasiran. Arrowhead is also in line to receive up to $535 million in additional milestone payments from Amgen and Royalty Pharma (NASDAQ: RPRX). The olpasiran therapy targets lipoprotein(a) to reduce cardiovascular disease risk. This milestone represents significant progress for Arrowhead, being the second TRiM-enabled candidate to enter Phase 3 trials, with more projected to follow in the coming year.
Amgen announced groundbreaking results from the Phase 3 E1910 trial, demonstrating that BLINCYTO combined with chemotherapy significantly improves survival for adults with Philadelphia chromosome-negative B-ALL. At 3.5 years, survival rates were 83% for those receiving BLINCYTO plus chemotherapy, compared to 65% for chemotherapy alone. The study, conducted by the ECOG-ACRIN Cancer Research Group, showed a 58% reduction in death risk with BLINCYTO. These findings will be submitted to regulatory authorities. No new safety concerns were noted, reinforcing BLINCYTO's efficacy in treating this challenging cancer.
Amgen (NASDAQ:AMGN) declared a $2.13 per share dividend for Q1 2023, reflecting a 10% increase from previous quarters. The dividend payment date is set for March 8, 2023, with record holders as of February 15, 2023. This positive adjustment demonstrates Amgen's commitment to returning value to shareholders amidst its ongoing developments in innovative therapeutics. The company continues to focus on high unmet medical needs while advancing its production capabilities and product pipeline.
Amgen (NASDAQ:AMGN) announced a webcast for the investment community at 8:00 a.m. ET on December 12, 2022, following its acquisition of Horizon Therapeutics. CEO Robert A. Bradway and the executive team will participate in the call, which will be accessible to media and the public. The event will be archived for 90 days on Amgen’s website. This acquisition highlights Amgen's commitment to addressing serious medical needs and expanding its innovative pipeline of therapeutics.
Amgen has announced a recommended cash offer for Horizon Therapeutics PLC, with Pillartree Limited, a subsidiary wholly owned by Amgen, acquiring Horizon's entire share capital at $116.50 per share. This represents a premium of approximately 47.9% over Horizon's November 29 closing price. The total transaction values Horizon at $27.8 billion, with an enterprise value of $28.3 billion. Amgen plans to finance this acquisition through a $28.5 billion bridge credit agreement, enhancing its portfolio in inflammation and nephrology, and is expected to drive revenue growth starting in 2024.
Amgen announced encouraging Phase 1 results for AMG 133, a novel bispecific molecule targeting obesity. The study reported a weight reduction of up to 14.5% at the highest dose (420mg Q4W) over 12 weeks. Most treatment-related adverse events were mild, primarily gastrointestinal. Based on the promising safety and efficacy results, Amgen is set to initiate a Phase 2 study in early 2023 to explore long-term effects. Overweight and obesity are significant global health issues, complicating patient health and healthcare systems.
Amgen will host a webcast call for investors at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease on Dec. 5, 2022, at 8:00 a.m. ET. David M. Reese, M.D., will present Phase 1 data on AMG 133, a novel bispecific receptor targeting GIPR and GLP-1. The webcast will be publicly accessible and archived for 90 days post-event.
Amgen, a leader in innovative human therapeutics, aims to address high unmet medical needs and has a robust pipeline. For more details, visit www.amgen.com.
